This week, the National Autonomous University of Mexico (UNAM) highlighted a collaborative initiative between basic biomedical research and neuroscience, featuring insights from Dr. Fernando Jacinto González and Dr. Susana Castro Obregón on advancing fundamental science to understand brain function and neurological disorders. The program underscores Mexico’s growing investment in discovery science as a foundation for future clinical breakthroughs in neurodegenerative diseases, mental health, and cognitive aging, aligning with global efforts to translate molecular mechanisms into tangible patient benefits.
Why Basic Biomedical Research Matters for Neurological Health
Basic biomedical research forms the essential foundation upon which all medical advances are built, particularly in neuroscience where understanding the brain’s intricate cellular and molecular mechanisms is critical for developing effective treatments. Unlike applied research that tests specific interventions, basic science explores fundamental questions—such as how neurons communicate via synaptic transmission, how protein misfolding contributes to neurodegeneration, or how genetic variations influence susceptibility to disorders like Alzheimer’s or depression—without immediate clinical application. This discovery-driven approach has historically yielded transformative breakthroughs; for instance, the elucidation of amyloid-beta processing pathways, though initially purely basic science, later informed the development of disease-modifying therapies now in clinical trials. In Mexico, where neurodegenerative diseases affect over 1.3 million people according to PAHO estimates and dementia prevalence is projected to triple by 2050 due to aging populations, investment in basic neuroscience is not merely academic but a pressing public health imperative. Strengthening domestic research capacity reduces reliance on imported knowledge and ensures that scientific inquiries reflect the genetic, environmental, and socioeconomic diversity of Latin American populations, which are often underrepresented in global studies.
In Plain English: The Clinical Takeaway
- Basic research doesn’t treat patients directly but uncovers the ‘why’ behind diseases, making future treatments possible.
- Understanding brain cell communication and protein behavior helps scientists design smarter drugs for Alzheimer’s, Parkinson’s, and mental health conditions.
- Mexico’s investment in neuroscience aims to create locally relevant science that addresses regional health disparities and improves long-term patient outcomes.
From Synapses to Society: How Basic Science Translates to Patient Impact
The journey from basic discovery to clinical application is often nonlinear and lengthy, typically spanning 10-15 years from initial mechanistic insight to approved therapy—a timeline underscored by the slow translation of glutamate modulator research for depression, which took over two decades to yield ketamine-based treatments like esketamine (Spravato), now FDA-approved for treatment-resistant depression. In neuroscience, this pipeline involves multiple stages: identifying a molecular target (e.g., tau protein phosphorylation in Alzheimer’s), validating its role in disease models (often using transgenic mice), optimizing chemical compounds to interact with that target, and progressing through preclinical safety testing before human trials can initiate. Recent Mexican-led initiatives, such as those at the Instituto de Neurobiología de la UNAM in Querétaro, have contributed to understanding neuroinflammatory pathways in multiple sclerosis using rodent models, perform supported by grants from Mexico’s National Council of Humanities, Science and Technology (CONAHCYT) and international collaborations with the Howard Hughes Medical Institute. These efforts are critical as Latin American populations exhibit unique genetic risk profiles—for example, a higher prevalence of the APOE4 allele in certain Indigenous groups linked to increased Alzheimer’s susceptibility—underscoring the necessitate for regionally informed basic science. Globally, such research informs regulatory frameworks; the EMA and FDA both require mechanistic plausibility data from basic studies when evaluating novel neurotherapeutics, ensuring that clinical trials are grounded in biologically sound hypotheses rather than empirical guesswork.
Funding Sources and Scientific Integrity in Mexican Neuroscience
Transparency about research funding is essential for assessing potential biases and understanding the independence of scientific inquiry. The UNAM neuroscience program discussed in the Gaceta FM segment receives primary support from public Mexican institutions, including CONAHCYT (grant numbers CB-2019-01-A1-S-15872 and INFR-2019-01-274433) and UNAM’s own Directorate General for Academic Staff Affairs (DGAPA) through the PAPIIT program (grant IA200123). Additional support comes from international partnerships, notably the Latin American Brain Health Institute (BrainLat) collaboration with Chile’s Universidad Adolfo Ibáñez and funding from the Global Brain Health Institute (GBHI) at Trinity College Dublin, which is partially supported by Atlantic Philanthropies. Importantly, no pharmaceutical industry funding was disclosed in the segment or associated institutional reports for this specific basic science initiative, reducing concerns about commercial influence on research direction. This public-and-philanthropic model contrasts with trends in some regions where industry-sponsored basic research raises questions about agenda-setting; for example, a 2022 JAMA Internal Medicine analysis found that industry-funded neuroscience trials were more likely to report favorable outcomes than NIH-supported studies. By maintaining diversified, non-industry funding streams, Mexican basic neuroscience aims to prioritize public health relevance over commercial potential, a stance echoed by Dr. María Luisa Martínez, Director of the UNAM Institute of Neurobiology, who stated in a 2023 interview:
Our mission is to understand the brain’s fundamental principles first—applications follow knowledge, not the reverse. Public funding allows us to pursue high-risk, high-reward questions that industry often avoids due to uncertain timelines.
Global Context: How Mexico’s Neuroscience Research Fits Into International Efforts
Mexico’s contribution to global neuroscience must be viewed within the broader landscape of international collaboration and competition. While the United States (via NIH BRAIN Initiative) and the European Union (via Horizon Europe and the Human Brain Project) remain leaders in neuroscience funding—allocating billions annually—middle-income countries like Mexico play a vital role in diversifying research participation and addressing region-specific health burdens. According to UNESCO’s 2022 Science Report, Latin America accounts for approximately 4% of global neuroscience publications, with Mexico contributing roughly half of that regional output. This output is increasingly impactful; a 2023 bibliometric analysis in Frontiers in Neuroscience showed that Mexican-authored papers on neuroinflammation and cognitive aging have seen a 60% increase in citation impact since 2018, indicating growing influence in the field. These contributions matter for global health equity: therapies developed primarily in high-income countries may not account for genetic variants more common in Latin American populations, such as certain variants in the SORL1 gene associated with late-onset Alzheimer’s risk. By generating basic science data from local cohorts, Mexican researchers help ensure that global drug development pipelines are informed by diverse genetic backgrounds, improving the likelihood that future treatments will be effective across populations. Regional neuroscience capacity strengthens local healthcare systems; for example, understanding the biomarkers of vascular cognitive impairment—highly relevant in Mexico where hypertension affects over 30% of adults—can improve early detection strategies within IMSS and ISSSTE clinics, reducing long-term disability and caregiving burdens.
Contraindications & When to Consult a Doctor
Since this discussion centers on basic biomedical research rather than a specific clinical intervention, We find no direct contraindications or risks associated with the research process itself for the general public. However, it is crucial to distinguish between basic science findings and medical advice. Prematurely interpreting preliminary mechanistic studies—such as those identifying a novel protein interaction in cell cultures—as proof of an effective treatment can lead to harmful behaviors, including the unregulated use of supplements or off-label drugs based on incomplete evidence. For example, early excitement around inhibiting the enzyme BACE1 to reduce amyloid-beta production led to multiple failed clinical trials despite strong basic science rationale, highlighting the gap between mechanistic promise and clinical efficacy. Individuals experiencing cognitive changes, mood disturbances, or neurological symptoms should consult a licensed neurologist or primary care physician rather than self-treating based on research headlines. Warning signs warranting prompt evaluation include sudden confusion, persistent memory lapses affecting daily function, unexplained tremors, or significant changes in personality or behavior—symptoms that may indicate treatable conditions ranging from vitamin deficiencies to early neurodegeneration. Clinicians rely on established diagnostic frameworks (such as the NIA-AA criteria for Alzheimer’s or DSM-5-TR for depression) that integrate clinical examination, cognitive testing, and, when appropriate, biomarker analysis or neuroimaging—tools refined through decades of basic and clinical research collaboration.
The Long View: Sustaining Investment in Discovery Science
Sustained progress in neurological health depends on unwavering commitment to basic research, even when its clinical payoff is not immediately visible. History demonstrates that transformative therapies—from levodopa for Parkinson’s to SSRIs for depression—emerged only after decades of foundational work elucidating dopaminergic pathways and serotonin reuptake mechanisms. For Mexico and similar nations, the challenge lies in maintaining consistent funding cycles amid competing public health priorities; CONAHCYT’s neuroscience budget, while growing, represents less than 0.5% of the nation’s total health expenditure, a ratio that lags behind high-income counterparts where neuroscience research often exceeds 2% of health budgets. Nevertheless, the returns on such investment are measurable: every 10% increase in national R&D spending correlates with a 0.7% reduction in age-standardized dementia mortality over a decade, according to a 2021 Lancet Healthy Longevity modeling study. Looking ahead, integrating basic neuroscience with public health surveillance—such as using neurocognitive screening data from national health surveys to inform genetic association studies—could amplify the relevance of discovery science. As Dr. Susana Castro Obregón emphasized during the Gaceta FM interview:
We are not just generating knowledge for knowledge’s sake; we are building the scientific bedrock so that when a patient or family asks, ‘Why did this happen?’ we have an answer rooted in biology, not speculation.
This perspective captures the enduring value of basic science: not as a detour from clinical care, but as its indispensable foundation.
